FDA ap­proves As­traZeneca's Lyn­parza com­bo for adults with BR­CA-mu­tat­ed prostate can­cer

In April, an FDA ad­comm gave the thumbs up to As­traZeneca’s block­buster PARP in­hibitor Lyn­parza la­bel ex­pan­sion in­to prostate can­cer — but on­ly for pa­tients whose …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER